Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity

Pharmacogenetics and Genomics

Volumn 21, Issue 10, 2011, Pages 652-664

  Wang, Danxin ^a   Para, Michael F ^a   Koletar, Susan L ^a   Sadee, Wolfgang ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

acetylator phenotype; allelic expression imbalance; cotrimoxazole; idiosyncratic drug reactions; N acetyltransferase; NAT1; polyadenylation; protein translation; sulfamethoxazole

Indexed keywords

ACYLTRANSFERASE; MESSENGER RNA; SULFAMETHOXAZOLE;

3' UNTRANSLATED REGION; ACETYLATOR PHENOTYPE; ALLELE; ARTICLE; B LYMPHOCYTE; DRUG HYPERSENSITIVITY; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; LIVER; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA TRANSLATION;

EID: 80052768747     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283498ee9     Document Type: Article

References (53)

1. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, Kawamura A. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 2008; 254:170-183.
2. Minchin RF, Hanna PE, Dupret JM,Wagner CR, Rodrigues-Lima F, Butcher NJ. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 2007; 39:1999-2005. (Pubitemid 47369238)
3. Butcher NJ, Arulpragasam A, Goh HL, Davey T, Minchin RF. Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 50-UTR splice variants with altered translational activities. Biochem J 2005; 387:119-127. (Pubitemid 40524081)
4. Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, et al. Functional properties of an alternative, tissue-specific promoter for human arylamine Nacetyltransferase 1. Pharmacogenet Genomics 2006; 16:515-525. (Pubitemid 43922348)
5. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW. Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos 2007; 35:1649-1656. (Pubitemid 47296060)
6. Husain A, Barker DF, States JC, Doll MA, Hein DW. Identification of the major promoter and non-coding exons of the human arylamine Nacetyltransferase gene (NAT1). Pharmacogenetics 2004; 14:397-406. (Pubitemid 38971230)
7. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 2005; 96:343-351. (Pubitemid 40676587)
8. Huang YS, Chern HD, Su WJ,Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883-889.
9. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255-258.
10. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49:13-17.
11. Zielinska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Mianowska K, Sekulska M. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprimsulfamethoxazole in infants. Pharm World Sci 1998; 20:123-130. (Pubitemid 28204307)
12. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M, Brenner H, Chang-Claude J. Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 2006; 15:99-107.
13. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507:65-77. (Pubitemid 35286541)
14. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
15. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1 *10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995; 55:5226-5229.
16. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995; 55:5230-5237.
17. Lammer EJ, Shaw GM, Iovannisci DM, Finnell RH. Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-Ntransferase (NAT1), and risk for orofacial clefts. Birth Defects Res A Clin Mol Teratol 2004; 70:846-852. (Pubitemid 39602195)
18. Lammer EJ, Shaw GM, Iovannisci DM, Van Waes J, Finnell RH. Maternal smoking and the risk of orofacial clefts: susceptibility with NAT1 and NAT2 polymorphisms. Epidemiology 2004; 15:150-156. (Pubitemid 40416968)
19. Jiao L, Doll MA, Hein DW, Bondy ML, Hassan MM, Hixson JE, et al. Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:2379-2386. (Pubitemid 351196371)
20. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006; 27:103-111. (Pubitemid 43025249)
21. Dai Y, Leng S, Li L, Niu Y, Huang H, Liu Q, et al. Effects of genetic polymorphisms of N-Acetyltransferase on trichloroethylene-induced hypersensitivity dermatitis among exposed workers. Ind Health 2009; 47:479-486.
22. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999; 58: 1759-1764. (Pubitemid 29505416)
23. de Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 2000; 58:288-299. (Pubitemid 30497472)
24. Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 1997; 233:584-591. (Pubitemid 27217693)
25. Zhu Y, Hein DW. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J 2008; 8:339-348.
26. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112:1013-1021.
27. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphisms in CYP3A4 affects hepatic expression and response to statin drugs. The Pharmacogenomics J 2010 [Epub ahead of print]. PMID: 20386561
28. Johnson AD, Gong Y, Wang D, Langaee TY, Shinn J, Cooper-Dehoff RM, et al. Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther 2009; 85:36-44.
29. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R, et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104:20552-20557.
30. Schneider MM, Nielsen TL, Nelsing S, Hoepelman AI, Eeftinck Schattenkerk JK, van der Graaf Y, et al. Efficacy and toxicity of two doses of trimethoprimsulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group J Infect Dis 1995; 171:1632-1636.
31. Ju C, Uetrecht JP. Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr Drug Metab 2002; 3:367-377. (Pubitemid 34778003)
32. Winter HR, Unadkat JD. Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos 2005; 33:969-976. (Pubitemid 41002779)
33. Nakamura H, Uetrecht J, Cribb AE, Miller MA, Zahid N, Hill J, et al. In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity. J Pharmacol Exp Ther 1995; 274: 1099-1104.
34. Reilly TP, Lash LH, Doll MA, Hein DW,Woster PM, Svensson CK. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114:1164-1173. (Pubitemid 30415234)
35. Zielinska E, Niewiarowski W, Bodalski J. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children. Eur J Clin Pharmacol 1998; 54:779-785. (Pubitemid 29024214)
36. Eliaszewicz M, Flahault A, Roujeau JC, Fillet AM, Challine D, Mansouri S, et al. Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. J Am Acad Dermatol 2002; 47:40-46.
37. Alfirevic A, Stalford AC, Vilar FJ,Wilkins EG, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003; 55:158-165. (Pubitemid 36237861)
38. Pirmohamed M, Alfirevic A, Vilar J, Stalford A, Wilkins EG, Sim E, Park BK. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10:705-713.
39. Carr A, Gross AS, Hoskins JM, Penny R, Cooper DA. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIVinfected patients. Aids 1994; 8:333-337. (Pubitemid 24094141)
40. O'Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 2002; 42:613-619. (Pubitemid 34547445)
41. Quirino T, Bonfanti P, Arcidiacono M, Pusterla L, Cagni A, Scaglione F, Milazzo F. Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity. Biomed Pharmacother 1999; 53:286-287.
42. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
43. Para MF, Finkelstein D, Becker S, Dohn M, Walawander A, Black JR. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000; 24:337-343.
44. Pinsonneault J, Nielsen CU, Sadee W. Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. J Pharmacol Exp Ther 2004; 311:1088-1096. (Pubitemid 39612715)
45. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C >T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704. (Pubitemid 41345321)
46. Liu L, Wagner CR, Hanna PE. Human arylamine N-acetyltransferase 1: in vitro and intracellular inactivation by nitrosoarene metabolites of toxic and carcinogenic arylamines. Chem Res Toxicol 2008; 21: 2005-2016.
47. Cheng Y, Miura RM, Tian B. Prediction of mRNA polyadenylation sites by support vector machine. Bioinformatics 2006; 22:2320-2325. (Pubitemid 44566959)
48. Hu J, Lutz CS,Wilusz J, Tian B. Bioinformatic identification of candidate cisregulatory elements involved in human mRNA polyadenylation. RNA 2005; 11:1485-1493. (Pubitemid 41396918)
49. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280:32618-32624. (Pubitemid 41368304)
50. Jacobson A, Peltz SW. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem 1996; 65: 693-739. (Pubitemid 26250623)
51. Wickens M, Anderson P, Jackson RJ. Life and death in the cytoplasm: messages from the 30 end. Curr Opin Genet Dev 1997; 7:220-232. (Pubitemid 27206761)
52. Edmonds M. A history of poly A sequences: from formation to factors to function. Prog Nucleic Acid Res Mol Biol 2002; 71:285-389.
53. Butcher NJ, Tiang J, Minchin RF. Regulation of arylamine Nacetyltransferases. Curr Drug Metab 2008; 9:498-504.